AstraZeneca to publish more vaccine trial data as US health agency raises questions

By Zoila Palma: AstraZeneca has indicated that it will publish more information on its US clinical trial after the US National Institute of Allergy and Infectious Diseases said it had been notified by the trial’s data and safety monitoring board (DSMB) that “it was concerned by information released by AstraZeneca on initial data from its Covid-19 vaccine clinical trial”.

The Financial Times report that the institute is concerned that AstraZeneca may have included outdated information from that trial which could have provided an incomplete view of the efficacy data.

Director of the Institute, Anthony Fauci said that he had never seen this happen before.

Fauci says that he and AstraZeneca received a “harsh note” from the data safety monitoring board.

According to Fauci, the vaccine is a very good vaccine and their actions just confuse the situation.

Meanwhile, AstraZeneca said that they will engage with the independent data safety monitoring board (DSMB) to share their primary analysis with the most up to date efficacy data.

The data safety monitoring board is an independent board of experts tasked to oversee ongoing clinical trials.

They worked with AstraZeneca on its American trial and the results showed that the vaccine was 79% effective at stopping symptomatic Covid-19 and 100 % effective at preventing people from falling seriously ill.

The trials also identified no overall safety issues relating to blood clots.

Advertise with the mоѕt vіѕіtеd nеwѕ ѕіtе іn Belize ~ We offer fully customizable and flexible digital marketing packages. Your content is delivered instantly to thousands of users in Belize and abroad! Contact us at mаrkеtіng@brеаkіngbеlіzеnеwѕ.соm or call us at 501-612-0315.

© 2021, BreakingBelizeNews.com. Content is copyrighted and requires written permission for reprinting in online or print media. Theft of content without permission/payment is punishable by law.